OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 13D and 13G filings for Heron Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 07:29 am Sale | 2022-12-30 | 13G | Heron Therapeutics, Inc. HRTX | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 0 0.000% | -8,275,000 (Position Closed) | Filing |
| 2022-02-14 11:17 am Purchase | 2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 8,275,000 8.120% | 8,275,000 (New Position) | Filing |